DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Basal Cell Carcinoma” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the basal cell carcinoma market,
comprising key marketed and pipeline drugs, epidemiology, clinical
trials, upcoming events, probability of success, patent information, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts
Key Takeaways:
-
The approved drugs in the basal cell carcinoma space target the immune
system, thymidylate synthase, and hedgehog signaling pathway. The
majority of these therapies are administered via the topical route,
with the remainder being oral formulations. -
The majority of industry-sponsored drugs in active clinical
development for basal cell carcinoma are in Phase II, with two drugs
in Phase III. -
Therapies in the pipeline for basal cell carcinoma focus on a wide
variety of targets. These drugs are administered via the topical,
oral, intravenous, and intratumoral routes. -
High-impact upcoming events for drugs in the basal cell carcinoma
space comprise topline Phase II trial results for Libtayo, and topline
Phase III trial results for Ameluz. -
The overall likelihood of approval of a Phase I solid tumors asset is
5.7%, and the average probability a drug advances from Phase III is
39.4%. Drugs, on average, take 9.5 years from Phase I to approval,
compared to 9.2 years in the overall oncology space. -
There have been five licensing and asset acquisition activities
involving basal cell carcinoma drugs during 2014-19. The $175m
agreement between Sun Pharmaceutical and Novartis made in December
2016 for the acquisition of Novartis’s branded oncology product Odomzo
by Sun Pharmaceutical was the largest deal. -
The distribution of clinical trials across Phase I-IV indicates that
the majority of trials for basal cell carcinoma have been in the early
and mid-phases of development, with 81% of trials in Phase I-II, and
only 19% in Phase III-IV. -
The US has a substantial lead in the number of basal cell carcinoma
clinical trials globally, while the UK leads the major EU markets. -
Clinical trial activity in the basal cell carcinoma space is dominated
by completed trials. Roche and Bausch Health have the highest number
of completed clinical trials for basal cell carcinoma, with 15 and 14
trials, respectively.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Basal cell carcinoma subtypes
TREATMENT
Electrodesiccation and curettage (ED&C)
Mohs micrographic surgery
Excisional surgery
Radiation therapy
Cryosurgery
Photodynamic therapy (PDT)
Laser surgery
Pharmacological therapies
EPIDEMIOLOGY
Recent incidence studies
MARKETED DRUGS
PIPELINE DRUGS
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
APPENDIX
Companies Mentioned
- Sun Pharmaceutical
- Novartis
- Roche
- Valeant Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/201lir
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Skin
Cancer Drugs